From Nasdaq: 2025-02-08 08:30:00

AbbVie and Gilead Sciences are two dividend stocks worth considering. AbbVie faced challenges with patent expiration and pipeline setbacks but remains strong with a forward P/E ratio of 15.5 and a 3.7% dividend yield. Gilead Sciences, with a forward P/E of 12.9, shows promise with its HIV products and diversified pipeline. Both companies have solid financials and dividend growth, making them attractive for income-seeking investors. Additionally, expert analysts are offering “Double Down” alerts for potential lucrative opportunities with select companies. It’s a chance worth considering for long-term growth.



Read more at Nasdaq: These 2 Dividend Stocks Are Absolute Bargains Right Now